1. Articles in category: Disease Classification

    1-24 of 87 1 2 3 4 »
    1. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

      Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349

      Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL

      Abstract BACKGROUND: Patients with newly diagnosed high-risk (HR) neuroblastoma (NBL) still have a poor outcome, despite multi-modality intensive therapy.

      Read Full Article
      Mentions: MIBG
    2. A single center clinical analysis of children with high-risk neuroblastoma.

      A single center clinical analysis of children with high-risk neuroblastoma.

      Oncotarget. 2017 Mar 07;:

      Authors: Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, Wang H, Duan X, Jin Y, Zhao Q

      Abstract The current multidisciplinary treatment for patients with high-risk neuroblastoma (NB) is the common census. However, protocols and opinions are different in different regions and institutions.

      Read Full Article
      Mentions: Treatment LDH
    3. High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      High-risk neuroblastoma in a sub-Saharan African country: telling it like it is.

      Trop Doct. 2017 Jan 01;:49475517704363

      Authors: Hadley GP, van Heerden J

      Abstract Neuroblastoma is uncommon in Africa, but when seen usually presents as high-risk disease with a poor prognosis. This aggressive biology of the tumour is frequently augmented by delayed presentation.

      Read Full Article
    4. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

      Oncogene. 2017 Apr 10;:

      Authors: Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G

      Read Full Article
      Mentions: MYCN
    5. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    6. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group

      Prior studies suggest that neuroblastomas that do not accumulate metaiodobenzylguanidine (MIBG) on diagnostic imaging (MIBG non-avid) may have more favorable features compared with MIBG avid tumors. We compared clinical features, biologic features, and clinical outcomes between patients with MIBG nonavid and MIBG avid neuroblastoma.

      Read Full Article
      Mentions: COG Imaging MYCN
    7. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Jpn J Clin Oncol. 2016 Jul;46(7):661-6

      Authors: Iehara T, Yagyu S, Tsuchiya K, Kuwahara Y, Miyachi M, Tajiri T, Sugimoto T, Sawada T, Hosoi H

      Abstract BACKGROUND: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma.

      Read Full Article
      Mentions: MIBG
    8. Management of Neuroblastoma: ICMR Consensus Document.

      Management of Neuroblastoma: ICMR Consensus Document.

      Indian J Pediatr. 2017 Apr 03;:

      Authors: Bansal D, Totadri S, Chinnaswamy G, Agarwala S, Vora T, Arora B, Prasad M, Kapoor G, Radhakrishnan V, Laskar S, Kaur T, Rath GK, Bakhshi S

      Abstract Neuroblastoma (NBL) is the most common extra-cranial solid tumor in childhood. High-risk NBL is considered challenging and has one of the least favourable outcomes amongst pediatric cancers.

      Read Full Article
      Mentions: Staging Relapse MYCN
    9. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      Cancer Cell Int. 2017;17:43

      Authors: Yue ZX, Huang C, Gao C, Xing TY, Liu SG, Li XJ, Zhao Q, Wang XS, Zhao W, Jin M, Ma XL

      Read Full Article
      Mentions: MYCN Bone Marrow LDH
    10. Study finds more childhood cancer survivors would likely benefit from genetic screening

      Study finds more childhood cancer survivors would likely benefit from genetic screening

      WASHINGTON, April 3, 2017 /PRNewswire/ -- Twelve percent of childhood cancer survivors carry germline mutations that put them or their children at increased risk of developing cancer, according to a landmark study presented today at the annual meeting of the American Association for...

      Read Full Article
    11. EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe

      HEMEL HEMPSTEAD, England and VIENNA, March 27, 2017 /PRNewswire/ -- EUSA Pharma (EUSA), a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency's (EMA) Committee for Medicinal...

      Read Full Article
      Mentions: Treatment
    12. Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid Cojec - a SIOPEN Study.

      Topotecan-Vincristine-Doxorubicin in Stage 4 High Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC - a SIOPEN Study.

      Cancer Res Treat. 2017 Mar 21;:

      Authors: Amoroso L, Erminio G, Makin G, Pearson AD, Brock P, Valteau-Couanet D, Castel V, Pasquet M, Laureys G, Thomas C, Luksch R, Ladenstein R, Haupt R, Garaventa A, SIOPEN Group

      Read Full Article
      Mentions: SIOPEN
    13. Organ motion in pediatric high-risk neuroblastoma patients using four-dimensional computed tomography.

      Organ motion in pediatric high-risk neuroblastoma patients using four-dimensional computed tomography.

      J Appl Clin Med Phys. 2017 Jan;18(1):107-114

      Authors: Kannan S, Teo BK, Solberg T, Hill-Kayser C

      Abstract PURPOSE/OBJECTIVE(S): High-risk neuroblastoma (HR-NBL) requires multimodality treatment, including external beam radiation of the primary tumor site following resection.

      Read Full Article
    14. Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Pediatr Blood Cancer. 2017 Mar 10;:

      Authors: Adams M, Traunecker H, Doull I, Cox R

      Abstract High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors.

      Read Full Article
    15. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.

      J Cancer Res Clin Oncol. 2017 Mar 11;:

      Authors: Cai J, Pan C, Tang Y, Chen J, Zhou M, Li B, Xue H, Shen S, Gao Y, Zhang A, Tang J

      Read Full Article
    16. Bronchiectasis following treatment for high-risk neuroblastoma: A case series

      High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors. This report outlines a case series of six patients who developed a chronic productive cough following treatment for HR neuroblastoma.

      Read Full Article
    17. The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      The TP53 gene rs1042522 C>G polymorphism and neuroblastoma risk in Chinese children.

      Aging (Albany NY). 2017 Mar 08;:

      Authors: He J, Wang F, Zhu J, Zhang Z, Zou Y, Zhang R, Yang T, Xia H

      Abstract TP53, a tumor suppressor gene, plays a critical role in cell cycle control, apoptosis, and DNA damage repair. Previous studies have indicated that the TP53 gene Arg72Pro (rs1042522 C>G) polymorphism is associated with susceptibility to various types of cancer.

      Read Full Article
    18. PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma.

      PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma.

      Clin Cancer Res. 2017 Mar 07;:

      Authors: Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D

      Read Full Article
      Mentions: MYCN PD-1
    19. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

      Lancet Oncol. 2017 Mar 01;:

      Authors: Ladenstein R, Pötschger U, Pearson AD, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D, SIOP Europe Neuroblastoma Group (SIOPEN)

      Abstract BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue ...

      Read Full Article
      Mentions: SIOPEN MYCN SIOP
    20. Advances in emerging drugs for the treatment of neuroblastoma.

      Advances in emerging drugs for the treatment of neuroblastoma.

      Expert Opin Emerg Drugs. 2017 Mar;22(1):63-75

      Authors: Berlanga P, Cañete A, Castel V

      Abstract INTRODUCTION: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis.

      Read Full Article
      Mentions: Treatment Relapse ALK
    1-24 of 87 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) COG
  4. Researches in the News

    1. (4 articles) MYCN
    2. (2 articles) LDH
    3. (1 articles) Imaging
    4. (1 articles) Bone Marrow
  5. General Informations in the News

    1. (3 articles) Treatment
    2. (1 articles) Staging
  6. Treatments in the News

    1. (3 articles) MIBG
    2. (1 articles) Relapse